Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Johnson & Johnson
Advertisement
Johnson & Johnson Launches Global DISH Surgical Outcomes System
August 24, 2026 | New Brunswick, New Jersey Johnson & Johnson announced the publication of the DISH Classification System,...
Johnson & Johnson Wins FDA Approval for IMAAVY in wAIHA
Spring House, Pennsylvania, U.S. | August 24, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration...
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Andelyn Biosciences Moves Forward With AAV9-GM2 Gene Therapy
Columbus, Ohio, August 18, 2026 Andelyn Biosciences, Inc., a patient-focused cell and gene therapy contract development and manufacturing organization...
Advertisements
Johnson & Johnson Defines Future of Surgical Intelligence
New Brunswick, New Jersey, August 18, 2026 Johnson & Johnson has published a new Future of Digital Surgery report...
Johnson & Johnson Advances MONARCH QUEST 3 Bronchoscopy
Santa Clara, California, August 17, 2026 Johnson & Johnson announced U.S. 510(k) regulatory clearance for MONARCH™ QUEST 3, the...
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Advertisement
